Once tumor cells metastasize to the bone, the prognosis for prostate cancer patients is generally very poor. The mechanisms involved in bone metastasis, however, remain elusive, because of lack of relevant animal models. In this manuscript, we describe step-by-step protocols for the xenograft mouse models that are currently used for studying prostate cancer bone metastasis. The different routes of tumor inoculation (intraosseous, intracardiac, intravenous and orthotopic) presented are useful for exploring the biology of bone metastasis.
Introduction
Prostate cancer is the second leading cause of cancer death in men in the US. Because of the recent improvement of treatment strategies for localized disease, a 5-year overall survival rate of over 90% has been achieved in prostate cancer patients (http://www.cancer.org/cancer/prostatecancer/detailedguide/ prostate-cancer-survival-rates). However, once cells spread to specific secondary organs such as bone, the 5-year survival rate of prostate cancer patients significantly decreases to 28% (http://www.cancer.org/cancer/prostatecancer/detailedguide/ prostate-cancer-survival-rates). Aside from the poor prognosis, bone metastasis significantly impairs the quality of life of prostate cancer patients, as it is associated with myelophthisis, hypercalcemia, bone pain, fracture and/or nerve compression. Therefore, there is an urgent need to understand the biology of bone metastasis in order to fight against this complex disease and its painful consequences.
Prostate cancer is known as a heterogeneous tumor. 1 For instance, some prostate cancers, when they disseminate to the bone, present both osteolytic and osteoblastic bone lesions, although bone metastasis from prostate cancer is classically classified as osteoblastic. In addition to tumor heterogeneity, bone marrow also contains heterogeneous populations, including hematopoietic lineage cells and cells regulating bone remodeling. The interaction between these bone marrow cells and cancer cells is thought to be important for cancer progression. 2 This heterogeneous and complex organization makes revealing the mysterious bone metastatic properties of prostate cancer much more difficult.
Metastasis involves multiple steps. First, tumor cells induce neovascularization (angiogenesis), acquire an invasive phenotype (epithelial mesenchymal transition), invade surrounding tissues (invasion), move into the circulation through the basal membrane (intravasation), travel throughout the body (circulation), and then adhere to a specific endothelium and disseminate into a secondary organ (extravasation). Once there, these disseminated tumor cells adapt to this new environment (colonization), survive for a long time without growing (dormancy), and eventually regrow (metastatic growth or recurrence). As this extremely complicated metastatic process is impossible to recreate with an in vitro or ex vivo approach, and experiments with humans are not reasonable, we need to rely on a pre-clinical approach with animal models to study bone metastasis. However, to date, there has been no ideal animal model that allows us to follow all these steps simultaneously.
Recently, in vivo xenograft mouse models have been developed that involve intraosseous, intracardiac, intravenous and orthotopic injections, which provide a means to better study prostate cancer bone metastasis. In this manuscript, we will provide details of the methods used in these animal models.
Xenograft mouse models for studying prostate cancer bone metastasis Murine xenograft models are commonly used for experimental bone metastasis. Tumor growth in marrow is achieved through injection of human cancer cell lines via different routes. Intravenous inoculation: 1-5 Â 10 6 cells per 100 ml.
Orthotopic inoculation: 1-5 Â 10 4 cells per 10 ml.
*NOTE: set up the experiment keeping time from harvest to injection at a minimum, to assure that the cells stay alive throughout the injection process. The viability of cells will decline with time. At the end of an injection experiment, the cell viability should be above 80%. *NOTE: surgery should be conducted under aseptic conditions and use sterile instruments, supplies and wound closure materials within a designated surgical room, and following procedures approved by the facility department of animal care oversight.
Preparation for surgery

Anesthetize animals if necessary.
This anesthesia should be performed only if equipped with a proper ventilated area. Two percent isoflurane mixed with 98% oxygen in the induction chamber. Mice should be kept under anesthesia for the duration of the surgery by being placed on their back and their head (nose) inserted into the breathing tube. Alternatively, xylazine-ketamine cocktail (Ketamine (100 mg ml À 1 ): Xylazine (20 mg ml
can be administered 300 ml per 1 kg body weight intraperitoneally (i.p.)
3. Monitor animals until fully anesthetized (loss of reflexes) and place them on a warming pad.
*NOTE: prior to surgery, depth of anesthesia should be ensured by gently pinching the hind paw or tail tip. Mice should be unresponsive. If there is a response (movement) wait longer or (in the case of ketamine injection) administer another small dose. Please consult with your local authority, as the regulation may vary. 4. Insert a 27G needle into the joint surface through the patellar tendon and tibial plateau in order to enter the intramedullary canal of the tibia.
*NOTE: the needle should be inserted with a drilling movement. Alternatively, an incision over the patellar tendon, followed by a longitudinal arthrotomy along the medial border of the patellar tendon, can be performed to expose the tibial plateau.
5. Inject the cancer cell suspension with a 30G needle via the proximal hole (10 ml maximal volume, but less volume would be ideal). 6. Inject an appropriate analgesic and monitor mice until they fully recover.
*NOTE: alternatively to this method, a needle can be used to drill a hole proximal to the tibial tuberosity. After penetration of the cortical bone, the cancer cell suspension can be injected.
*NOTE: bone marrow ablation creates space for the injection, and drilled holes can be sealed with bone wax preventing cancer cells to migrate out of the medullary cavity. (please see Method 2).
Intraosseous inoculation (Method 2)
1. Place the animal in supine position on a heated operation table within the laminar flow (administer anesthesia as indicated above).
*NOTE: tape the animal's hind limb to the operation table (if the leg is tape-fixed over a needle cap with a rotation to the inner side, drilling of the holes is facilitated) (Figures 2b and c) .
2. Disinfect the hind limb with 70% ethanol. 3. Make a skin incision with a scalpel starting slightly below the knee joint to the end of the tibial bone marrow cavity (Figure 2d ).
*NOTE: take care to not damage the tibial vein or artery.
4. Carefully resect the caput mediale of the gastrocnemius along the anterior tibial margin, and then continue to resect *NOTE: the dental drill bit should be held perpendicular to the tibia while drilling. Flush the bone marrow with 0.5 ml 1 Â PBS using a 30G needle. 8. Insert bone wax with a capillary piston into the distal hole and press with a spatula. 9. Inoculate the cancer cell suspension intramedullarily with a 30G needle via the proximal hole (10 ml maximal volume, but less volume would be ideal). 10. Seal the proximal hole with bone wax and suture the wound with 2-3 stitches. 11. Disinfect the wound with betadine. 12. Inject an appropriate analgesic and monitor mice until they fully recover.
*NOTE: both Method 1 and Method 2 are invasive. Either the injection channel using Method 1 or the drilled holes using Method 2 will be identified in histological sections. The injection volume has to be kept minimal for both methods because of the space limitation in the medullary cavity.
*NOTE: mice should be monitored regularly, according to an approved mouse protocol, and killed if clinical signs match the experimental end point. Signs include, but are not limited to, rapid weight loss and any condition interfering with daily activities (for example, eating or drinking, ambulation or elimination).
*NOTE: bone lesions can be monitored by radiography (Faxitron, 25 kV, 6 s) (Figures 3a and b: representative radiography pictures of osteolytic and osteoblastic bone metastases), and cancer cell growth can be monitored using bioluminescence imaging (only for luciferase-labeled cells). Ring finger and little finger are used to withdraw and push the plunger, respectively (Figure 4a ). 2. Use thumb and index finger of the other hand to slightly squeeze the rib cage of mouse from dorsal side upward to raise the position of the heart (Figure 4b ) (administer anesthesia as indicated above). 3. Disinfect the chest area with 70% ethanol. 4. Insert needle horizontally into the injection point and slightly withdraw the plunger after the needle has been inserted 7-8 mm.
*NOTE: push and withdraw the plunger of syringe several time to reduce friction force before loading the syringe with 120 ml cell suspensions (20 ml in excess).
*NOTE: alternatively, needle can be inserted vertically. *NOTE: injection point is 1-2 mm left of the midline and 1-2 mm beneath the edge of rib cage of the mouse (Figure 4c ).
*NOTE: if the needle is properly inserted in the left ventricle, bright red blood will be pumped back into the cell suspension and pulsation should be visible from the air bubble remaining in the syringe (Figure 4d ). If there is no blood pumping back or dark red blood observed, retract and re-insert the needle, but no more than three attempts should be carried out within 24 h.
5. Inject the cell suspension at a slow pace (B30 s for total 100 ml).
*NOTE: avoid positional change of injecting hand during injection.
*NOTE: correct injection can be verified during the process of injection by the color of blood pumped back to syringe. Should the needle be correctly injected into the left ventricle, bright red, oxygenated arterial blood will be seen, which is distinctive from the darker venous blood of the right ventricle (Figure 5a ).
*NOTE: tumor cells in the systemic circulation can also be verified within 24 h after injection by bioluminescence imaging, if you are using luciferase-labeled cells. If tumor cells are correctly injected into the left heart ventricle, bioluminescence signals can be observed in the whole body (Figure 5b) . Otherwise, signals will be concentrated in the chest area, and resemble the shape of lung, or will be completely absent (Figure 5c ).
Slightly withdraw the plunger during the inoculation, and
observe whether blood is still pumping back into the syringe to confirm that the needle is still placed in the left ventricle. 7. Complete the injection of 100 ml of cell suspension with the 20 ml excess remaining in the syringe. Wait for 5 s before the needle is taken out. 8. Monitor mice until they fully recover.
*NOTE: after the successful injection, the mouse is placed back into a clean cage on a heating pad, until fully recovered from the anesthesia. Closely monitor the mouse for the first 24 h after injection. Gently grab the tail of a mouse and pull it into the commercial or custom mouse restrainer, with its back against the slit and its tail sticking out of the small opening in the back of the restrainer. Slowly close doors and keep mouse gently restrained. 2. Find the lateral tail vein ( Figure 6 ) and promote vasodilation of the vein for easy injection by warming the mouse using a heat lamp or a warming device or by immersion of the tail in warm water for about 5 min.
*NOTE: the time will be dependent on the distance from the heat source, and the animals must be monitored carefully to prevent being burned or overheated by the heat source.
3. Disinfect the tail with 70% ethanol. 4. Pull the tail straight. 5. Hold the tip of tail with thumb, and support the point for injection with the index finger. 6. With the bevel facing up, insert a needle into one of the lateral tail veins in the proximal 1/3 of the tail, and gently inject 100 ml of the cell suspension.
*NOTE: a successful injection is based on lack of resistance while pushing the plunger. *NOTE: start from the distal end of the tail; thus, if the first trial fails, a more proximal region of the tail can be used if another attempt is needed.
*NOTE: the maximum volume that may be injected depends on numerous factors including the mouse's size, background strain and properties of the cells. Most users try to limit the injection to a maximum of 0.25 ml. Keep in mind that overconcentration of cells may lead to embolism in lung capillaries and death of the mice.
7. Withdraw the needle after injection and press a clean piece of paper towel or cotton swab on the injection site to facilitate clotting. 8. Release the mouse from the restrainer and return it to the cage.
*NOTE: most mice show only reduced activity levels. The mice should be observed for the first hour following injection. If no problems are observed other than reduced activity, the mice may be returned to standard housing. 7. Retract the needle gently and place a cotton swab over the injection site for about 1 min to prevent bleeding and spillage of material. 8. Return the prostate to the peritoneum and suture the abdominal wall first and the skin layer after with a 4-0 silk suture. 9. Disinfect the wound with betadine. 10. Inject an appropriate analgesic and monitor mice until they fully recover.
*NOTE: mice should be monitored regulary according to an approved mouse protocol and killed if clinical signs match experimental end point. Signs include, but are not limited to, rapid weight loss and any condition interfering with daily activities (for example, eating or drinking, ambulation or elimination).
In vivo bioluminescence imaging Materials 1. Luciferase-labeled prostate cancer cell line (PCa-luc cells). 4. Set exposure time and imaging parameters. 5. Anesthetize the mice in 2% isoflurane mixed with 98% oxygen in induction chamber. 6. Place mice in the IVIS platform while keeping mice under anesthesia through a nose cone, and take the image 12 min after D-luciferin injection.
*NOTE: it is recommended to perform an initial kinetic experiment for each animal model taking images during different time points. This will allow you to determine the D-luciferin distribution for your experiment.
7. Analyze and quantify the photons emitted from luciferaselabeled cells within the animal according to the manufacturer's protocol.
*NOTE: for the intravenous inoculation model of prostate cancer, a highly metastatic cancer cell line (for example, PC-3 and DU145) typically gives rise to many metastases, especially at hind limb with bone metastatic lesions (Figure 8a) , whereas very few metastases will be detected from a poorly metastatic cancer cell line (for example, LNCaP and LNCaP C4-2B).
*NOTE: bioluminescence is a well-established technique commonly utilized to track tumor growth and to locate and monitor the presence of metastases within living animals. In vivo bioluminescence imaging system is a highly sensitive imaging technology to quantify bioluminescence via a digital camera and advanced computer software. This system detects photons emitted from luciferase-expressing cells within the living animals. *NOTE: in certain cases, it may be important to get both dorsal and ventral images.
*NOTE: many imaging techniques can also be used to detect the prostate cancer metastatic lesions in mice, such as molecular imaging techniques or small animal diagnostic imaging (microcomputed tomography or magnetic resonance imaging or Faxitron cabinet x-ray systems) (Figure 8b) . If both bioluminescence and other imaging techniques are not available, histopathological examination of metastatic nodules subsequent to necropsy is the best approach.
Discussions/Conclusion
In this manuscript, we discussed the mouse xenograft models that are commonly used to study prostate cancer bone metastasis. Using these models with human prostate cancer cell lines (Table 1) , we have gained a greater understanding of the process of bone metastasis. However, there are limitations for using these xenograft models, as the immune systems of animals used for developing these models are weak or compromised to avoid an immune response to the human tissue. There are currently some transgenic spontaneous prostate cancer models that may overcome this limitation; however, the transgenic mice currently available rarely result in bone metastases, unlike those seen in human prostate cancer. 29 Although humanized animal models 30, 31 or ex vivo tissue engineered models 32, 33 have been recently proposed to potentially mimic bone metastasis, models that perfectly recapitulate the human prostate cancer bone metastatic process are still missing. To unveil the mystery of bone metastasis, further improvement of animal models currently available and/or development of new animal models to overcome the limitations that we are facing are clearly warranted.
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